Patients with DDI, % (n) 24.5% (267) | Patients without DDI, % (n) 75.6% (825) | P value | |
Gender | |||
Males | 21.6% (147) | 78.4% (534) | 0.006 |
Females | 29.2% (120) | 70.8% (291) | |
Age, mean±SD (years) | 62.3±12.7 | 56.3±12.5 | <0.001 |
Age ≥65 years | 45.7% (122) | 26.2% (226) | <0.001 |
HCV genotype | |||
1 | 83.9% (224) | 65.6% (541) | <0.001 |
2 | 3.4% (9) | 6.3% (52) | 0.097 |
3 | 5.2% (14) | 15.7% (130) | <0.001 |
4 | 7.5% (20) | 12.4% (102) | 0.037 |
Fibrosis stage | |||
F0-1 | 15.7% (42) | 17.2% (142) | 0.640 |
F2 | 29.6% (79) | 32.5% (268) | 0.419 |
F3 | 22.5% (60) | 24.0% (198) | 0.669 |
F4 | 32.2% (86) | 26.3% (217) | 0.073 |
HIV co-infection (excluding ART) | 14.6% (39) | 13.0% (107) | 0.495 |
HIV co-infection (including ART) | 39.3% (105) | 5.0 (41) | <0.001 |
Hepatocellular carcinoma | 5.2% (14) | 2.9% (24) | 0.106 |
Liver transplant recipient | 5.2% (14) | 3.5% (29) | 0.207 |
HCV viral load, log UI/mL (median) | 6.2 (3.7–8.3) | 6.2 (2.0–8.9) | 0.989 |
HCV viral load ≥ 61 UI/mL | 59.9% (160) | 59.9% (494) | |
eGFR ≥60 mL/min | 88.8% (237) | 92.4% (762) | 0.067 |
Previous antiviral treatment: | |||
Naïve | 75.7% (202) | 71.6% (591) | 0.201 |
Treatment-experienced | 24.3% (65) | 28.4% (234) | 0.201 |
Response to previous antiviral treatment: | |||
Recurrent | 52.3% (34) | 54.3% (127) | 0.779 |
Null responder | 10.8% (7) | 17.1% (40) | 0.215 |
Regrowth | 4.6% (3) | 3.4% (8) | 0.650 |
Partial responder | 10.8% (7) | 14.1% (33) | 0.485 |
Unknown | 21.5% (14) | 11.1% (26) | 0.029 |
DAAs: | |||
LDV/SOF±RBV | 51.6% (138) | 48.7% (402) | 0.401 |
DCV/LDV±RBV | 4.9% (13) | 15.8% (130) | <0.001 |
VEL/SOF±RBV | 1.9% (5) | 3.2% (26) | 0.274 |
PTV/OBV/RTV/DBV±RBV | 33.7% (90) | 17.8% (147) | <0.001 |
SMV/SOF±RBV | 0.8% (2) | 2.9% (24) | 0.044 |
SOF+RBV | 0.8% (2) | 3.8% (31) | 0.013 |
PTV/OBV/RTV+RBV | 2.6% (7) | 1.9% (16) | 0.500 |
ELB/GRZ | 3.7% (10) | 5.9% (49) | 0.168 |
DAAs adherence | 99.6% | 99.2% | 0.707 |
ART, antiretroviral treatment; DAAs, direct-acting antivirals; DBV, dasabuvir; DCV, daclatasvir;DDI, drug–drug interactions; ELB, elbasvir; GRZ, grazoprevir; LDV, ledipasvir; OBV, ombitasvir; PTV, paritaprevir; RBV, ribavirin;RTV, ritonavir; SMV, simeprevir; SOF, sofosbuvir; VEL, velpatasvir; eGFR, estimated glomerular filtration rate.